{"Clinical Trial ID": "NCT01033032", "Intervention": ["INTERVENTION 1:", "- Amrubicin", "Systemic treatment with amrubicin"], "Eligibility": ["Incorporation criteria:", "Women >=18 years of age.", "The histological diagnosis of HER2-negative breast cancer. The negativity HER-2 should be confirmed by one of the following:", "(FISH ratio < 2.2), or", "IHC 0-1+, or", "IHC 2-3+ AND FISH-negative (FISH ratio <2.2)", "Evidence of metastatic or locally advanced breast cancer, inoperative.", "Minimum of 1 and maximum of 2 chemotherapy treatments for metastatic breast cancer.", "Patients who have previously received anthracycline are eligible provided that their previous anthracycline is 6 months prior to entry into the study.", "A measurable disease by RECIST version 1.1 criteria", "The left ventricular ejection fraction (LVEF) is 350% by echocardiogram (ECHO) or multi-door acquisition scan (MUGA).", "Patients should have a QTc interval of <=450 msec.", "No major intercurrent medical conditions or heart disease.", "Patients should be >= 3 weeks after the last chemotherapy and recover from all acute toxicity except alopecia.", "The performance status of the Eastern Cooperative Oncology Group (ECOG PS) of 0-2.", "Adequate function of the organ, including the following functions:", "ANC >=1500 cells/mL", "Number of platelets >=100,000 cells/mL", "Hemoglobin >=9 g/dL", "Total Bilirubin <=1.5 x ULN; AST/ALT <=2.5 x ULN, (except for liver metastases, then <=5 x ULN)", "Serum creatinine <1.5 x ULN", "Women of childbearing potential must undergo a negative serum or urinary pregnancy test <=7 days before starting treatment. If a woman becomes pregnant or suspects that she is pregnant while participating in this study, she must agree to inform her attending physician immediately.", "Patients should be available for treatment and follow-up.", "Patients should be able to understand the experimental nature of this study and give their informed consent in writing prior to entering the study.", "Patients on anti-coagulation are acceptable if therapeutic anti-coagulation is stable. In addition, the patient's INR should be adequate if the patient is receiving coumadine therapy.", "Prior hormonal treatment for metastatic breast cancer is permitted; however, treatment should be discontinued before the patient is enrolled in this study.", "- Exclusion criteria:", "Any concomitant treatment with any other experimental, chemotherapeutic or hormonal treatment.", "Prior treatment with >=3 cytotoxic treatments for advanced disease. (Any number of prior hormonal treatments are acceptable as long as treatment is discontinued before the patient is enrolled in this study).", "Major surgery or systemic treatment <=3 weeks of study treatment.", "\u00b7 High-dose chemotherapy requiring haematopoietic stem cell support.", "A radiotherapy prior to > 25% of the bone marrow.", "Uncontrolled brain metastases Patients with treated brain metastases (resection or radiation therapy) are eligible if brain metastases have responded to treatment as documented by CT or MRI at >=2 weeks after the end of radiation therapy, neurological symptoms are absent and steroids have been discontinued.", "- Suspected, diffuse idiopathic, interstitial pulmonary disease or pulmonary fibrosis.", "\u2022 Diagnosis of second malignancy over the last 3 years (except for in situ cervix carcinoma, squamous or basal cell skin cancer, thyroid cancer, in situ channel carcinoma (CDIS) or lobular carcinoma in situ (LCIS).", "One of the following situations <=12 months prior to starting treatment:", "Myocardial infarction;", "Severe unstable angina;", "Congestive heart failure;", "- Heart dysrhythmia continues.", "Family history of idiopathic cardiomyopathy or uncontrolled cardiac arrhythmia.", "Patients with previous allergy or hypersensitivity to anthracyclines.", "Patients who had a 10% decrease in LVEF during previous treatment with anthracycline.", "* Palliative radiation therapy in metastatic breast cancer areas must have been completed >7 days prior to the first treatment dose of the study. The exception is radiation therapy for brain metastases, which must be completed >=21 days prior to the treatment of the study. (Note: Any measurable lesion that has already been irradiated will not be considered a target lesion).", "A serious and intercurrent concomitant illness, including, but not limited to, continuous or active infection, psychiatric illness or social situations that would limit compliance with the requirements of the study.", "\u2022 History of HIV seropositivity or patients receiving immunosuppressive drugs that increase the risk of neutropenic complications.", "A mental state that would prevent patients from understanding the nature and risk of the study.", "The use of an unapproved or experimental agent <=30 days of administration of the first dose of the drug under study. Patients may not receive any other experimental or anticancer treatment during their participation in this study."], "Results": ["Performance measures:", "Survival without progression (SPF) of patients with BAT/Phase II", "The progression is defined in RECIST v1.1 as a 20% increase in the sum of the longest diameter of the target lesions, a measurable increase in a non-target lesion or the appearance of new lesions. This measurement of results is reported for all patients treated at the same dose level and is not separated in Phase I and Phase II. The results of Phase I and Phase II are not separated because the time of registration (beginning of Phase 1 or later Phase II) is not relevant for the measurement of results.", "Time: every 6 weeks until disease progression", "Results 1:", "Title of the arm/group: Ambubicine", "Description of the arm/group: Systemic therapy with amrubicin", "Total number of participants analysed: 66", "Median (95% confidence interval)", "Unit of measure: month 4.0 (2.5 to 5.8)"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/3 (33.33 per cent)", "NEUTROPENIA FEBRILE 0/3 (0.00 %)", "LYMPH PAIN NODE 0/3 (0.00 %)", "- NEUTROPHIL CUNT DECREASED 0/3 (0.00 %)", "THROMBOCYTOPENIA 0/3 (0.00 %)", "- CHEST PAIN 0/3 (0.00 %)", "DEHYDRATION 0/3 (0.00 %)", "1/3 (33.33%)", "- PNEUMONITIS 0/3 (0.00 %)", "PULMONARY INFILTERATES 0/3 (0.00 %)", "ALOPECIA 0/3 (0.00 %)"]}